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SecretionExtracellular matrix protein 1 (ECM1) is expressed in a wide variety of tissues and plays important
roles in extracellular matrix formation. Additionally, ECM1 gene mutations cause lipoid proteinosis
(LP), a rare skin condition of genetic origin. However, an effective therapeutic approach of LP is not
established. Here, we showed that ECM1 gene mutation observed in LP patients signiﬁcantly
suppresses its secretion. As ECM1 has three putative N-glycosylation sites and most of mutated
ECM1 observed in LP patients are defective in these N-glycosylation sites, we investigated the
correlation between LP and N-glycosylation of ECM1. We identiﬁed that the Asn354 and Asn444 res-
idues in ECM1 were N-glycosylated by mass spectrometry analysis. In addition, an N-linked glycan
at Asn354 negatively regulated secretion of ECM1, contrary to LP patient-derived mutants. These
results indicate that the defect of N-glycosylation in ECM1 is not involved in the aberration of secre-
tion of LP-derived mutated ECM1.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Extracellular matrix protein 1 (ECM1) plays important roles in
extracellular matrix formation, cell signaling, and regulation of
differentiation in tissues [1]. ECM1 is a secretory protein initially
isolated from an osteogenic stromal cell line and is constructed
by a 19-amino-acid signal peptide and four functional domains: a
cysteine-free N-terminal segment, two tandem repeats, and a
C-terminal segment [2]. Several studies identiﬁed that ECM1 pro-
motes angiogenesis, cell proliferation, and embryonal chondrogen-
esis [3–5]. Moreover, ECM1 inhibits matrix metalloproteinase 9
activity by high-afﬁnity interaction [6]. Previous studies have
shown that it also interacts with ﬁbulin-1C/1D and perlecan, which
are components of basement membrane protein, a thin sheet of
ﬁbers underlying the epithelium, including skin [7,8].
Additionally, an ECM1 gene mutation causes lipoid proteinosis
(LP), also known as Urbach–Wiethe disease, which is a rare autoso-
mal recessive genodermatosis mainly observed in the NorthernCape province of South Africa [9]. LP is characterized by hoarseness
because of inﬁltration of the vocal cords and thickening of the skin.
Moreover, these patients show vascular anomalies caused by
excessive deposition of hyaline-like material and consequent dis-
ruption/reduplication of basement membrane around blood ves-
sels. It has been reported previously that exons 6 and 7 are the
most common sites for ECM1 mutations in LP [10]. Since most of
these mutations are nonsense mutations such as Q276X and
W359X (Fig. 1A) or frameshift mutations, synthesis of full-length
ECM1 is abolished. Although there have been many therapeutic tri-
als in LP, including oral steroids and oral dimethyl sulfoxide
(DMSO) [11,12], a deﬁnite therapeutic approach is not established.
Here, we focused on N-glycosylation in ECM1. Glycosylation is
one of the post-translational modiﬁcation reactions categorized
into three types: N-glycosylation, O-glycosylation, and C-mannosy-
lation. In the case of N-glycosylation, a glycan preassembled on a
dolichol-phosphate carrier is transferred to Asn residues that are
part of the consensus sequence Asn-Xaa-Ser/Thr (where Xaa can
be any amino acid except Pro), and it is processed by a number
of glycosidases and glycosyltransferases in the endoplasmic reticu-
lum (ER) and the Golgi apparatus [13]. Previous report estimates
that approximately 70–90% of the consensus sequence is glycosyl-
ated [14]. N-Glycosylation is involved in cellular processes, such as
protein folding, intracellular trafﬁcking, enzyme activity, and pro-
tein secretion [15]. Moreover, it is correlated with the pathogenesis
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Fig. 1. Suppression of lipoid proteinosis-derived ECM1 secretion. (A) Schematic diagram of human ECM1 protein. ECM1 mutations observed in LP patients are indicated by
the black inverted triangles. Signal peptide is indicated by the black box. (B) HT1080-neo, HT1080-ECM1-MH, HT1080-ECM1-Q276X-MH, and HT1080-ECM1-W359X-MH
cells were cultured in serum-free media for 24 h. Subsequently, conditioned media and cell lysates were collected. Conditioned media were incubated with Ni-NTA agarose
for 2 h at 4 C. The bound proteins were eluted with 300 mM imidazole. Obtained samples were subjected to SDS–PAGE. The proteins were detected by immunoblotting with
anti-c-myc or anti-a-tubulin antibodies.
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been reported to play various roles, but its roles seem to differ
depending on the glycosylated protein.
In this study, we analyzed the correlation between LP and
N-glycosylation of ECM1. ECM1 has putative N-glycosylation sites:
Asn354, Asn444, and Asn530, which exist in exon 7 and C-terminal
domain. Since the mutations of ECM1 frequently observed in LP
patients are nonsense mutation in exons 6 and 7 [10], LP-derived
mutated ECM1 is thought to be defective in N-glycosylation.
Although some reports previously showed that ECM1 is
N-glycosylated at Asn444 [18,19], the correlation between LP and
N-glycosylation of ECM1 and the role of N-glycosylation on ECM1
remain unclear. This study identiﬁed all N-glycosylation sites in
ECM1 and revealed that the defects in N-glycosylation in ECM1
are not responsible for the aberration in the secretion of LP-derived
mutated ECM1.
2. Materials and methods
2.1. Cell culture
Human ﬁbrosarcoma HT1080 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Nissui, Tokyo, Japan), supple-
mented with 5% fetal bovine serum (FBS), 100 mg/L kanamycin,100 units/mL penicillin G, 600 mg/L L-glutamine, and 2.25 g/L
NaHCO3 at 37 C in a humidiﬁed incubator with 5% CO2.
2.2. Construction of plasmids
The humanC-terminally tagged ECM1-Myc-His6 expression vec-
tor was generated by cloning human ECM1 cDNA from HL-60 cDNA
into the pCI-neo vector. The c-myc and His6 epitopes were fused
after Pro275 (Q276X) or Thr358 (W359X) of human ECM1. The
sequences of primers used for the mutagenesis were as follows:
ECM1-Q276X-MH and ECM1-W359X-MH, 50-TTTTCTCGAGATGGG
GACCACAGCCAG-30 (forward) and ECM1-Q276X-MH 50-GATGAGT
TTTTGTTCGGGAGCTTCCTCC-30 (reverse); and ECM1-W359X-MH
50-GATGAGTTTTTGTTCTGTACAGGTGTG-30 (reverse).
The ECM1N354Q-Myc-His6 mutant, the ECM1N444Q-Myc-His6
mutant, and theN354Q/N444Qdoublemutant (designated as ECM1
2NQ-Myc-His6) expression vectors were constructed by substitut-
ing Asn354 and/or Asn444 with Gln by using the overlap extension
technique [20]. The sequences of primers used for the mutagenesis
were as follows: ECM1-N354Q-MH, 50-CGCCAGGGGAACCAACAC
ACCTGTAC-30 (forward) and 50-GTACAGGTGTGTTGGTTCCCCTGGC
G-30 (reverse); ECM1-N444Q-MH, 50-GGCTGATCCACCAAATGACTG
CCCGC-30 (forward) and 50-GCGGGCAGTCATTTGGTGGATCAGCC-30
(reverse).
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lines
The stable cell lines expressing wild-type or mutant ECM1-
myc-his6 were established by transfecting the vectors into
HT1080 cells and maintained in medium supplemented with
375 lg/mL G418 (Roche Applied Sciences, Indianapolis, IN). The
stable cell lines that expressed high levels of myc-his6-tagged
wild-type ECM 1, ECM1 (Q276X), ECM1 (W359X), ECM1
(N354Q), ECM1 (N444Q), and ECM1 (2NQ; N354Q and N444Q)
were designated as HT1080-ECM1-MH, HT1080-ECM1-Q276X-
MH, and HT1080-ECM1-W359X-MH, HT1080-ECM1-N354Q-MH,
HT1080-ECM1-N444Q-MH, and HT1080-ECM1-2NQ-MH cells,
respectively. The cells transfected with pCI-neo were designated
as HT1080-neo [21,22].
2.4. Western blot
Cells were cultured in 60-mm dishes with or without tunicamy-
cin for 24 h, washed twice with phosphate-buffered saline (PBS),
and lysed in a lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% sodium
deoxycholate, and 1 mM phenylmethylsulfonyl ﬂuoride) at 4 C
with sonication. The lysates were centrifuged at 14,000 rpm for
10 min at 4 C, and the protein concentrations were determined
by staining with Coomassie Brilliant Blue G-250 (Bio-Rad Laborato-
ries, Hercules, CA). The samples were resolved using SDS–
polyacrylamide gel electrophoresis (SDS–PAGE), transferred onto
a PVDF membrane, immunoblotted with anti-c-myc (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) or anti-a-tubulin (Sigma–
Aldrich, St. Louis, MO) antibodies, and visualized using an LAS
4000 mini (GE Healthcare, Waukesha, WI) [23–25].
2.5. Detection of secreted ECM1
The cells were cultured in serum-free media. After 24 h, the con-
ditioned media and the cell lysates were collected. The conditioned
media incubated with Ni-NTA agarose for 2 h at 4 C. Ni-NTA aga-
rose was washed with PBS, and Ni-NTA-bound ECM1 was eluted
with 300 mM imidazole. The cell lysates were lysed as described
above. The obtained samples were added with loading buffer
(350 mM Tris–HCl, pH 6.8, 30% glycerol, 0.012% BPB, 6% SDS, 30%
2-ME) and boiled for 3 min. Secondly, the samples were resolved
using SDS–PAGE, transferred onto a PVDFmembrane, and immuno-
blotted with anti-c-myc or anti-a-tubulin antibodies [26].
2.6. Puriﬁcation of recombinant extracellular matrix protein 1 from
cell culture medium
HT1080-ECM1-MH cells were cultured in serum-free medium
for 24 h. After 24 h, conditioned medium was collected and incu-
bated with Ni-NTA agarose for 2 h at 4 C. Ni-NTA agarose (Qiagen,
Hilden, Germany) was washed with PBS, and Ni-NTA-bound ECM1
was eluted with 300 mM imidazole. The obtained samples were
subjected to SDS–PAGE and stained with Coomassie Brilliant Blue
R-250 [27–29].
2.7. Liquid chromatography–mass spectrometry
Recombinant ECM1 puriﬁed from conditioned media was dena-
tured using 1% SDS at 95 C for 5 min and was diluted 1:10 with 1%
Triton X-100. To deglycosylate the denatured protein, the sample
was treated using peptide N-glycosidase F (PNGaseF; Roche Diag-
nostics GmbH, Mannheim, Germany) according to the manufac-
turer recommendations. Both deglycosylated and untreated
samples were subjected to SDS–PAGE. After CBB staining, a visibleband was excised and destained. In-gel digestion was performed
using trypsin (TPCK-treated, Worthington Biochem. Co., Freehold,
NJ). The digestion mixture was separated using a nanoﬂow LC
(Easy nLC, Thermo Fisher Scientiﬁc, Waltham, MA) on a PepMap
RSLC analytical column (C18, u50 lm  15 cm, 2 lm, 100 Å,
Thermo Fisher Scientiﬁc) with a linear gradient of 0–35% buffer B
(100% ACN and 0.1% formic acid) at a ﬂow rate of 300 nL/min over
10 min and subjected on-line to a Q Exactive mass spectrometer
(Thermo Fisher Scientiﬁc) with a nanospray ion source. MS and
MS/MS data were acquired using a data-dependent top5 method.
Obtained MS/MS data were searched against an in-house database,
including the ECM1 sequence, using the MASCOT program (Matrix
Science, London, UK) with variable modiﬁcations: Gln? pyro-Glu
(N-term Q), Oxidation (M), Propionamide (C), Hex (W).
2.8. MALDI-TOF MS
Puriﬁed recombinant ECM1 was subjected to SDS–polyacryl-
amide gels. After CBB staining, the bands were excised with trypsin
(TPCK-treated, Worthington Biochem. Co.). The digests were
desalted using ZipTip C18l tips (EMD Millipore Co., Billerica,
MA) and applied to MALDI-TOF MS on an ultraﬂeXtreme TOF/TOF
MS (Bruker Daltonics, Bremen, Germany) in reﬂector mode using
a-cyano-4-hydroxycinnamic acid as the matrix. The selected peaks
were analyzed by MS/MS in LIFT mode.3. Results
3.1. Suppression of lipoid proteinosis-derived ECM1 protein secretion
Previous reports have shown that ECM1 mutations are
frequently observed in LP patients and clinical features caused by
ECM1 mutations have been well investigated. However, the
underlying mechanisms by which ECM1 mutations cause LP have
not been analyzed. Therefore, we analyzed the phenotypes of
LP-derived mutant ECM1-overexpressing cells compared with
wild-type ECM1-overexpressing cells.
First, we established ECM1-overexpressing HT1080 cell lines
(HT1080-ECM1-MH) and established cell lines overexpressing
mutant forms of ECM1 observed in LP patients (Q276X and
W359X) in HT1080 cells. Subsequently, we tried to examine the
secretion levels of two ECM1 mutants. We investigated the levels
of secreted ECM1 from HT1080-neo, HT1080-ECM1-MH, HT1080-
ECM1-Q276X-MH, and HT1080-ECM1-W359X-MH cells. As a
result, secreted Q276X and W359X were not observed (Fig. 1B),
suggesting that aberration of ECM1 secretion is one of the causes
of LP. We revealed for the ﬁrst time that LP-derived mutant
ECM1 was less secreted compared with wild-type ECM1.
3.2. ECM1 is N-glycosylated at Asn354 and Asn444 residues
Previous report showed that nonsense mutations in exons 6 and
7 of ECM1 are frequently observed in LP patients [10]. Moreover,
three putative N-glycosylation sites in ECM1 exist between exon
7 and the C-terminal domain (Fig. 2A). Thus, N-linked glycan can-
not attach to mutated ECM1 observed in LP patients. Furthermore,
some studies have reported that N-linked glycan is important for
protein secretion [21,22,30–32]. For these reasons, we hypothe-
sized that the aberrant N-glycosylation by gene mutation in
ECM1 is one of the causes of LP. To validate this hypothesis, we
analyzed N-glycosylation of ECM1.
First, we examined whether ECM1 is N-glycosylated or not. We
treated HT1080-neo and HT1080-ECM1-MH cells with tunicamy-
cin, an inhibitor of protein N-glycosylation. Our data showed that
treatment of HT1080-ECM1-MH cells with tunicamycin led to a
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Fig. 2. Treatment of tunicamycin suggested N-glycosylation within ECM1. (A) Schematic diagram of human ECM1 protein. ECM1 mutations observed in LP patients are
indicated by the black inverted triangles. Three putative N-glycosylation sites (Asn354, Asn444 and Asn530) are indicated by sugar chains. Signal peptide is indicated by the
black box. (B) HT1080-neo and HT1080-ECM1-MH cells were treated with tunicamycin (TM) at various concentrations (0, 0.1, 1, and 10 lg/mL) for 24 h. The cells were lysed,
and aliquots of the cell lysates were subjected to SDS–PAGE. The proteins were detected by immunoblotting with anti-c-myc or anti-a-tubulin antibodies.
882 S. Uematsu et al. / FEBS Open Bio 4 (2014) 879–885size reduction of ECM1-MH (Fig. 2B), suggesting that ECM1 was N-
glycosylated.
Next, we performed mass spectrometry analysis to determine
the N-glycosylation sites in ECM1. Recombinant ECM1 was puri-
ﬁed from conditioned medium of HT1080-ECM1-MH cells using
Ni-NTA agarose (Fig. 3A). Puriﬁed recombinant ECM1 was digested
with trypsin and was treated with or without PNGase F. The result-
ing peptides were analyzed by MALDI-TOF MS or LC–MS. LC–MS
was used when the peptide fragment including putative
N-glycosylated Asn residue could not be detected by MALDI-TOF
MS. Because PNGase F cleaves between the innermost GlcNAc
and Asn residues of N-linked glycans, thereby converting Asn to
Asp residues, the new peaks of the fragment showing conversion
of glycosylated Asn to Asp can be observed by mass spectrometry
analysis. With PNGase F treatment, the peptide fragment including
Asp that was converted from Asn354 residue was observed at b3
(283.10) to b5 (535.19) by LC–MS/MS (Fig. 3B). Similarly, with
PNGase F treatment, the peptide fragment including Asp that
was converted from Asn444 residue was observed at m/z 1360.7
by MALDI-TOF MS (Fig. 3C). However, the peak of the fragment
including Asn530 was detected by LC–MS, even though the sample
was treated with or without PNGase F (Fig. 3D). Moreover, the
peak of the fragment including Asp that was converted from
Asn530 residue was not observed (Fig. 3D). These results indicate
that the Asn354 and Asn444 residues, but not Asn530, are
N-glycosylated.
To further conﬁrm the N-glycosylation of ECM1, we prepared
Asn-to-Gln single and doublemutants corresponding toN-glycosyl-
ated Asn residues and established cell lines overexpressing mutant
forms of ECM1 (N354Q, N444Q, and 2NQ) in HT1080 cell lines
(Fig. 4A). Western blotting of these stable cell lines revealed that
the molecular size of the single mutant was lower than that of
wild-type ECM1 and that the molecular size of the double mutant
(2NQ) was lower than that of the single mutant (N354Q and
N444Q) (Fig. 4A). Subsequently, we treated HT1080-ECM1-MHand HT1080-ECM1-2NQ-MH cells with tunicamycin. Treatment
with tunicamycin led to a size reduction of wild-type ECM1 but
not 2NQ (Fig. 4B). Moreover, the molecular size between wild-type
ECM1 treated with tunicamycin and 2NQ was the same. These
results indicate that ECM1 is N-glycosylated at the Asn354 and
Asn444 residues.
3.3. N-Glycosylation regulates secretion of ECM1
Since the secretion levels of ECM1 mutants (Q276X and
W359X) observed in LP patients were suppressed, we investigated
the role of N-glycosylation for secretion of ECM1 to elucidate a link
between LP and N-glycosylation of ECM1.
Our data showed that the levels of secreted ECM1-N354Q-MH
and ECM1-2NQ-MH mutants were higher than that of wild-type
ECM1. On the other hand, the levels of secreted wild-type ECM1-
MH and ECM1 N444Q-MH were approximately the same
(Fig. 4C). These results indicate that N-glycosylation at Asn354 neg-
atively regulates the secretion of ECM1, whereas N-glycosylation at
Asn444 has no effect on the secretion. Since ECM1 gene mutation
observed in LP patients (Q276X and W359X) signiﬁcantly sup-
presses its secretion, the aberrant N-glycosylation in ECM1 does
not seem to be the cause of LP directly.
4. Discussion
ECM1 plays important roles in cell proliferation, angiogenesis,
and extracellular matrix formation [1,4]. Mutations in the ECM1
gene are identiﬁed in patients of skin disease, LP, for which an
effective treatment has not be established [11]. We examined the
effect of ECM1 mutations that are observed in LP patients
(Q276X and W359X) on its secretion and revealed for the ﬁrst time
that the levels of each secreted mutant were signiﬁcantly lower
than that of wild-type ECM1 (Fig. 1B), suggesting that aberration
of ECM1 secretion is one of the causes of LP.
Fig. 3. N-Glycosylation of human ECM1 at Asn354 and Asn444. (A) HT1080-ECM1-MH cells were cultured in serum-free medium for 24 h. Subsequently, conditioned medium
was collected and incubated with Ni-NTA agarose for 2 h at 4 C. The bound proteins were eluted with 300 mM imidazole, subjected to SDS–PAGE, and detected by CBB
staining. (B) Puriﬁed recombinant ECM1 was treated with PNGaseF and subjected to SDS–PAGE. The sample that was digested with trypsin was analyzed by LC–MS/MS.
Asn354 was converted to Asp residue (underlined ‘‘D’’) by treatment with PNGaseF. (C) Puriﬁed ECM1 was treated with (lower) or without (upper) PNGaseF and subjected to
SDS–PAGE. The samples that were digested with trypsin were analyzed by MALDI-TOF MS. The peak of the fragment in which Asn444 was converted to Asp residue
(underlined ‘‘D’’) by PNGaseF was observed at m/z 1360.7. (D) Puriﬁed ECM1 was treated with (lower) or without (upper) PNGaseF and subjected to SDS–PAGE. The samples
that were digested with trypsin were analyzed by LC–MS. The peak of the fragment including Asn530 was observed at 7.8 min both after treatment with or without PNGaseF.
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reaction that attaches an N-linked glycan to an Asn residue, which
is a part of the consensus sequence. It mostly participates in pro-
tein folding, intracellular trafﬁcking, enzyme activity, and protein
secretion [15]. Previous reports have shown that ECM1 is N-glycos-
ylated at Asn444 [18,19]. However, the underlying biological func-
tions of glycosylation in ECM1 are yet to be reported. In this
study, we studied the correlation between LP and N-glycosylation
through identiﬁcation of the all N-glycosylation sites in ECM1.
We demonstrated that ECM1 is N-glycosylated at Asn354 and
Asn444 by mass spectrometry analysis (Fig. 3B and C). This is the
ﬁrst report identifying the N-glycosylation sites of ECM1 com-
pletely. Moreover, we demonstrated that N-glycosylation at
Asn354 negatively regulates the secretion of ECM1 (Fig. 4C). It has
been reported that the secretion of many N-glycosylated proteins
is positively regulated by their glycosylation, contrary to ECM1
[21,22,30–32]. Although, further studies are needed to know why
N-glycosylation of ECM1 negatively regulates its secretion, we
speculated that an N-linked glycan at Asn354 might be recognized
by some factors, thereby suppressing the secretion of ECM1. Based
on our observations, the secreted levels of ECM1 mutants observed
in LP patients were lower than that of wild-type ECM1, contrary to
N-glycosylation-defective mutants. Thus, contrary to our hypothe-
sis, we conclude that aberrant N-glycosylation is not the cause of
LP. We speculated that suppression of LP mutants secretion might
be attributed to conformational changes of ECM1 by gene muta-
tions observed in LP patients, thereby allowing it to be degraded
by ER-associated degradation. Besides, the skin of LP patients showhyperkeratosis and basement membrane thickening at the dermal-
epidermal junction [1]. Possibly, these phenotypes may result from
the reduction of secreted levels of ECM1 in LP patients. However,
the possibility cannot be excluded that the N-glycosylation pat-
terns may be different between in vitro and in human tissues
because we evaluated using ECM1-overexpressing cell lines in this
study.
Meanwhile, ECM1 has a putative C-mannosylation site at Trp359
(the consensus sequence is Trp-Xaa-Xaa-Trp/Cys; Trp359-Lys-
Ala-Trp). C-mannosylation is a unique type of glycosylation that
covalently attaches an a-mannopyranosyl residue to the indole
C2 carbon atom of tryptophan via a C–C linkage [33]. We also ana-
lyzed whether ECM1 is C-mannosylated by mass spectrometry and
revealed that ECM1 was not C-mannosylated (data not shown). On
the other hand, we demonstrated that ECM1 is O-glycosylated at
Ser525 and/or Thr526 (data not shown). O-glycosylation attaches a
sugar chain to an oxygen atom of serine/threonine and seems to
inﬂuence proteolytic processing and protein folding [34]. We
intend to analyze the roles of O-glycosylation on ECM1 and its rela-
tionship to LP in future work.
In conclusion, we identiﬁed that the ECM1 gene mutation
observed in LP patients signiﬁcantly suppresses its secretion. Addi-
tionally, we revealed that ECM1 is N-glycosylated at two sites,
Asn354 and Asn444 and N-glycosylation at Asn354 negatively regu-
lates the secretion of ECM1. These results indicate that LP is unre-
lated to N-glycosylation of ECM1. Our results contribute to the
understanding of the mechanisms of LP and provide new insights
into ECM1 function.
Fig. 4. Negative regulation of ECM1 secretion by N-glycosylation at Asn354. (A)
HT1080-neo, HT1080-ECM1-MH, HT1080-ECM1-N354Q-MH, HT1080-ECM1-
N444Q-MH, and HT1080-ECM1-2NQ-MH cells were lysed, and aliquots of the cell
lysates were subjected to SDS–PAGE. The proteins were detected by immunoblot-
ting with anti-c-myc or anti-a-tubulin antibodies. (B) HT1080-neo, HT1080-ECM1-
MH, and HT1080-ECM1-2NQ-MH cells were treated with tunicamycin (TM) at
various concentrations (0, 0.1, 1, and 10 lg/mL) for 24 h. The cells were lysed, and
aliquots of the cell lysates were subjected to SDS–PAGE. The proteins were detected
by immunoblotting with anti-c-myc or anti-a-tubulin antibodies. (C) HT1080-neo,
HT1080-ECM1-MH, HT1080-ECM1-N354Q-MH, HT1080-ECM1-N444Q-MH, and
HT1080-ECM1-2NQ-MH cells were cultured in serum-free media for 24 h.
Subsequent conditioned media and cell lysates were collected. Conditioned media
were incubated with Ni-NTA agarose for 2 h at 4 C. The bound proteins were eluted
with 300 mM imidazole. Obtained samples were subjected to SDS–PAGE. The
proteins were detected by immunoblotting with anti-c-myc or anti-a-tubulin
antibodies.
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